Author

Shawnta Lorthridge‐Jackson

Observed name: Shawnta Lorthridge-Jackson

Institution: Incyte (United States)

Observed institution: Incyte (United States)

OpenAlex ID: A5117076594

Ruxolitinib for Emergency Treatment of COVID‐19–Associated Cytokine Storm: Findings From an Expanded Access Study

2025 · Jeffrey Weinstein, Nikhil Jagan, et al. · The Clinical Respiratory Journal · 4

Implementation of a Novel Patient-Reported Outcome Collection System in THRIVE, a Prospective, Longitudinal, Observational cohort study of Patients at Risk for Chronic Graft-Versus-Host Disease

2026 · Shawnta Lorthridge-Jackson, Alyssa Schmidt, et al. · Transplantation and Cellular Therapy

Clinical and Disease Characteristics of Initial Participants at Time of Enrollment in THRIVE, a Prospective, Longitudinal, Observational cohort study of Patients at Risk for Chronic Graft-Versus-Host Disease

2026 · Catherine J. Lee, Doris M. Ponce, et al. · Transplantation and Cellular Therapy

Clinical and disease characteristics of initial participants at time of enrollment in THRIVE, a prospective, observational cohort study of patients at risk for chronic graft‑versus‑host disease

2025 · Catherine Lee, Doris Ponce, et al. · Blood

Works count: 4

Citation count: 4

H-index: 1

I10-index: